Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer

Anikó Maráz, József Furák, Zoltán Varga, Emese Fodor, Zsófia Együd, Emoke Borzási, Zsuzsanna Kahán, Regina Pálföldi, László Tiszlavicz, Katalin Hideghéty

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Dosimetric data and acute oesophageal toxicity (AET) during chemoradiotherapy (CRT) were evaluated in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Fifty patients were treated with paclitaxel-based conformal CRT with a mean±SD dose of 60.7±9.8 Gy. The oesophageal toxicity was prospectively registered and evaluated in relation to the maximal dose (Dmax), mean dose (Dmean), length and volume of oesophagus irradiated with 35-60 Gy (V35-60Gy), and according to the seriousness of AET. Results: Dmax and D mean to the oesophagus were 57.0±10.8 Gy and 24.9±9.0 Gy, respectively. AET of grade 1, 2 and 3 developed in 16 (32%), 14 (28%) and three (6%) cases, respectively. The Dmax, Dmean, length and the V35-60Gy were all related to dysphagia (p<0.001). V 45Gy was the most reliable predictor of AET of grade 2 or more. Conclusion: Our results indicate that keeping oesophageal V45Gy below 32.5% can prevent severe AET during CRT of NSCLC.

Original languageEnglish
Pages (from-to)1737-1742
Number of pages6
JournalAnticancer research
Volume33
Issue number4
Publication statusPublished - Apr 1 2013

Keywords

  • Lung cancer
  • Oesophageal toxicity
  • Paclitaxel-based chemoradiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this